Stephens Investment Management Group LLC Buys 151,106 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Stephens Investment Management Group LLC boosted its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 9.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,706,915 shares of the medical device company's stock after acquiring an additional 151,106 shares during the quarter. Stephens Investment Management Group LLC owned 2.56% of Tandem Diabetes Care worth $32,704,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. AlphaQuest LLC boosted its holdings in Tandem Diabetes Care by 138.7% during the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after acquiring an additional 541 shares during the period. Jones Financial Companies Lllp boosted its holdings in Tandem Diabetes Care by 195.8% during the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock valued at $41,000 after acquiring an additional 748 shares during the period. Assetmark Inc. boosted its holdings in Tandem Diabetes Care by 77.5% during the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock valued at $44,000 after acquiring an additional 535 shares during the period. NBC Securities Inc. purchased a new stake in Tandem Diabetes Care in the 1st quarter worth approximately $37,000. Finally, State of Wyoming lifted its holdings in Tandem Diabetes Care by 95.9% in the 4th quarter. State of Wyoming now owns 2,996 shares of the medical device company's stock worth $108,000 after buying an additional 1,467 shares during the period.

Tandem Diabetes Care Stock Up 3.6%

TNDM stock traded up $0.55 during midday trading on Wednesday, hitting $15.75. The stock had a trading volume of 1,832,499 shares, compared to its average volume of 1,499,592. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -5.67 and a beta of 1.48. The business has a 50-day moving average of $19.93 and a two-hundred day moving average of $24.04. Tandem Diabetes Care, Inc. has a 52-week low of $14.87 and a 52-week high of $48.24. The company has a debt-to-equity ratio of 1.99, a current ratio of 2.30 and a quick ratio of 1.81.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.07). The firm had revenue of $234.42 million during the quarter, compared to analysts' expectations of $220.19 million. Tandem Diabetes Care had a negative return on equity of 57.33% and a negative net margin of 18.71%. Tandem Diabetes Care's revenue for the quarter was up 22.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.65) earnings per share. As a group, equities research analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TNDM. Wall Street Zen cut Tandem Diabetes Care from a "hold" rating to a "sell" rating in a report on Saturday, June 21st. Mizuho began coverage on Tandem Diabetes Care in a report on Thursday, April 10th. They issued a "neutral" rating and a $20.00 price objective for the company. Wells Fargo & Company dropped their price objective on Tandem Diabetes Care from $22.00 to $20.00 and set an "equal weight" rating for the company in a report on Thursday, May 1st. Citigroup reiterated a "sell" rating and issued a $14.00 price objective (down previously from $24.00) on shares of Tandem Diabetes Care in a report on Wednesday, July 9th. Finally, Robert W. Baird dropped their price objective on Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating for the company in a report on Thursday, May 1st. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $32.71.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.